Lyora Therapeutics has launched with seed funding to advance its pipeline of biologically validated, “one-and-done” therapies targeting the root cause of inherited retinal diseases through the clinic.
The company’s lead program, LYA-101, for treatment of retinitis pigmentosa caused by pathogenic variants in the PRPF31 gene, is designed to reverse symptoms in patients by augmenting expression of PRPF31. The second program, LYA-102, for treatment of Usher Syndrome Type 2, uses an optimized CRISPR technology to address mutations in exon 13 of the USH2A gene. This program may also translate into a therapeutic option for hearing loss.
The Rhode Island-based biotech has raised $2.5 million in pre-seed funding and plans to submit an IND for LYA-101 within the next 18 months, with LYA-102 following closely behind.
Lyora has appointed Pam Stetkiewicz, Ph.D., formerly COO of Arbor Bio, as CEO.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!